MicroRNAs and angiosarcoma: are there promising reports? DOI Creative Commons
Amir Modarresi Chahardehi, Arya Afrooghe,

Nikoo Emtiazi

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: May 17, 2024

In recent years, microRNAs (miRNAs) have garnered increasing attention for their potential implications in cancer pathogenesis, functioning either as oncogenes or tumor suppressors. Notably, angiosarcoma, along with various other cardiovascular tumors such lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations the expression of specific miRNA subtypes. A substantial body evidence underscores pivotal involvement miRNAs genesis angiosarcoma certain tumors. This review aims to delve into current literature on prospective applications malignancies, a focus angiosarcoma. It comprehensively covers diagnostic methods, prognostic evaluations, treatments while providing recapitulation angiosarcoma’s risk factors molecular an emphasis role miRNAs. These insights can serve groundwork designing randomized control trials, ultimately facilitating translation these findings clinical applications. Moving forward, it is imperative studies thoroughly scrutinize advantages disadvantages compared approaches Closing knowledge gaps will be crucial harnessing full realm research.

Language: Английский

mRNA vaccines: a new era in vaccine development DOI

Shubhra Chandra,

Jennifer C Wilson,

David M. Good

et al.

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Journal Year: 2024, Volume and Issue: 32(10), P. 1543 - 1564

Published: Jan. 1, 2024

The advent of RNA therapy, particularly through the development mRNA cancer vaccines, has ushered in a new era field oncology. This article provides concise overview key principles, recent advancements, and potential implications vaccines as groundbreaking modality treatment. represent revolutionary approach to combatting by leveraging body's innate immune system. These are designed deliver specific sequences encoding cancer-associated antigens, prompting system recognize mount targeted response against malignant cells. personalized adaptive nature holds immense for addressing heterogeneity tailoring treatments individual patients. Recent breakthroughs exemplified success COVID-19 have accelerated their application platform's versatility allows rapid adaptation vaccine candidates various types, presenting an agile promising avenue therapeutic intervention. Clinical trials demonstrated encouraging results terms safety, immunogenicity, efficacy. Pioneering candidates, such BioNTech's BNT111 Moderna's mRNA-4157, exhibited outcomes targeting melanoma solid tumors, respectively. successes underscore elicit robust durable anti-cancer responses. While great promise, challenges manufacturing complexities cost considerations need be addressed widespread adoption. scalable cost-effective processes, along with ongoing clinical research, will pivotal realizing full vaccines. Overall, cutting-edge that promise transforming As research progresses, refining processes crucial advancing these from mainstream oncology practice, offering hope patients fight cancer.

Language: Английский

Citations

7
Chitosan nanovectors for siRNA delivery: New horizons for nonviral gene therapy DOI
Mahdi Rahimi, Zahra Kariminezhad,

Elsa-Patricia Rondon

et al.

Carbohydrate Polymers, Journal Year: 2025, Volume and Issue: unknown, P. 123581 - 123581

Published: April 1, 2025

Language: Английский

Citations

0
Application of Advanced CRISPR/Cas-9 and Other Genomic Tools in RNA-Based Therapeutics DOI

Tehreem Fatima Awan,

Muhammad Jadoon Khan

Published: Jan. 1, 2025

Language: Английский

Citations

0
Role of the microRNA in Prediction of the Breast Cancer DOI
Maryam Kheiry, Farajolah Maleki

Journal of Basic Research in Medical Sciences, Journal Year: 2025, Volume and Issue: 12(2), P. 11 - 20

Published: April 1, 2025

Language: Английский

Citations

0
Targeting the RUNX3–miR-186-3p–DAT–IGF1R axis as a therapeutic strategy in a Parkinson’s disease model DOI Creative Commons
Peng Huang,

Zhiting Wan,

Shaogang Qu

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Aug. 5, 2024

With the increasing age of population worldwide, incidence rate Parkinson's disease (PD) is annually. Currently, treatment strategy for PD only improves clinical symptoms. No effective can slow down progression disease. In present study, whole transcriptome sequencing was used to obtain mRNA and miRNA expression profiles in a mouse model, which revealed pathogenesis PD. The transcription factor RUNX3 upregulated miR-186-3p model. Furthermore, high be targeted inhibit DAT expression, resulting decrease dopamine content dopaminergic neurons. Moreover, IGF1R prevent activation IGF1R–P-PI3K–P-AKT pathway, thus apoptosis neurons by regulating cytochrome c–Bax–cleaved caspase-3 pathway. Our research showed that RUNX3–miR-186-3p–DAT–IGF1R axis plays key role PD, potential target

Language: Английский

Citations

1
MicroRNAs and angiosarcoma: are there promising reports? DOI Creative Commons
Amir Modarresi Chahardehi, Arya Afrooghe,

Nikoo Emtiazi

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: May 17, 2024

In recent years, microRNAs (miRNAs) have garnered increasing attention for their potential implications in cancer pathogenesis, functioning either as oncogenes or tumor suppressors. Notably, angiosarcoma, along with various other cardiovascular tumors such lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations the expression of specific miRNA subtypes. A substantial body evidence underscores pivotal involvement miRNAs genesis angiosarcoma certain tumors. This review aims to delve into current literature on prospective applications malignancies, a focus angiosarcoma. It comprehensively covers diagnostic methods, prognostic evaluations, treatments while providing recapitulation angiosarcoma’s risk factors molecular an emphasis role miRNAs. These insights can serve groundwork designing randomized control trials, ultimately facilitating translation these findings clinical applications. Moving forward, it is imperative studies thoroughly scrutinize advantages disadvantages compared approaches Closing knowledge gaps will be crucial harnessing full realm research.

Language: Английский

Citations

0